Compare iShares Bitcoin Trust (IBIT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Novartis AG — how do they compare? iShares Bitcoin Trust trades at $37.7, while Novartis AG trades at $154.81 (market cap $290.25B). The key difference: Novartis AG pays a 3.17% dividend while iShares Bitcoin Trust pays none, and Novartis AG is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| IBIT | NVS | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $71.29 | $168.62 |
52-Week Low | $33.29 | $113.50 |
Market Cap | — | $290.25B |
Enterprise Value | — | $330.27B |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $36.89, up 1.49% with neutral technical signals. The stock shows mixed momentum with bearish moving averages but neutral oscillators. Recent news highlights IBIT's position as a leading Bitcoin ETF with $44.9 billion in assets under management, surpassing Fidelity's competing fund. The ETF faces headwinds from significant outflows in June 2026 but maintains institutional interest as a preferred Bitcoin exposure vehicle.
Outlook remains cautious amid Bitcoin market volatility and ETF outflow pressures. Investment opportunity lies in IBIT's dominant market position and institutional adoption, balanced against cryptocurrency market risks and competitive ETF landscape. Key risks include Bitcoin price sensitivity and regulatory uncertainty affecting fund flows.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
